91.1 F
San Fernando
Thursday, Mar 28, 2024
Array

Cynvenio to Sell Cancer Test in U.S.

Cynvenio Biosystems Inc. announced Monday a collaborative partnership with Korean biotech company ATGen Global to bring a new cancer test to the U.S. market. The WestlakeVillage-based biotech will sell ATGen’s NK Vue, a blood test that measures activity of Natural Killer cells, which are immune-system cells that fight off infections and cancer. Exceptionally low levels of Natural Killer cells have been linked to an increased risk of developing autoimmune diseases and cancer. NK Vue is approved by regulatory authorities in Canada and Korea. For the U.S. market, Cynvenio will sell and support it as a “laboratory developed test,” a type of diagnostic tool that must be completely performed by one lab and do not require FDA approval. The test will provide U.S. physicians a means to monitor overall immune health. Financial details of the agreement were not disclosed. Clinical trials are in the works in the U.S., Korea, Canada, Denmark and China testing NK Vue’s effectiveness when monitoring different cancer types, such as breast, lung, colorectal, prostate, gastric and ovarian cancers. There are also several on-going trials measuring Natural Killer cell activity in autoimmune diseases. “We are confident that NK Vue will provide a consistently reliable and affordable means to measure NK cell activity, while spawning new studies that will result in clinically relevant associations with a wide range of diseases not yet explored,” Dr. Paul Song, chief medical officer at both Cynvenio and ATGen, said in a statement.

Featured Articles

Related Articles